GO
Loading...

Takeover Bids

More

  • In this excerpt from a "Squawk Box" interview on October 2, 2012, Pershing Square's Bill Ackman said he had bought some stock and expressed his concerns about the company to its Board.

  • Ackman: P&G Has Stumbled Over Past Few Years     Tuesday, 2 Oct 2012 | 7:40 AM ET

    P&G has been one of the great growth companies of all times but quite frankly it has stumbled over the past couple of years under the current CEO's leadership, said William Ackman, Pershing Square Capital Management founder & CEO, discussing the problems at Procter & Gamble.

  • Equity Firms Like Bain Are Depicted as Colluding Wednesday, 12 Sep 2012 | 10:01 AM ET
    Bain Capital headquarters, Bostonb Mass.

    In court documents that lawyers for Bain Capital sought to keep secret, the company and other leading private equity firms are depicted as unofficial partners in a bid-rigging conspiracy aimed at holding down the prices of businesses they were seeking to buy, The New York Times reports.

  • Finding Value in Health Care Stocks     Monday, 10 Sep 2012 | 8:57 AM ET

    Dinakar Singh, TPG-Axon Capital CEO, discusses the best way to play the health care space.

  • Short Regional Banks: Singh     Monday, 10 Sep 2012 | 8:41 AM ET

    Dinakar Singh, TPG-Axon Capital CEO, discusses the best way to trade financials after the banking crisis.

  • Does QE3 Really Matter?     Monday, 10 Sep 2012 | 8:03 AM ET

    "Ultimately, I don't think lower rates make that much difference anymore," says Dinakar Singh, TPG-Axon Capital CEO, sharing his thoughts on additional Fed easing.

  • A Thrifty Bid by Hertz?     Friday, 24 Aug 2012 | 10:20 AM ET

    CNBC's Kayla Tausche reports Hertz is upping its bid for Dollar Thrifty, and a look at how to play the takeover bid, with Fred Lowrance, Avondale Partners.

  • Faber Report: Peltz Wins IR Board Seat     Monday, 13 Aug 2012 | 9:41 AM ET

    CNBC's David Faber reports shareholder activism is on the rise and Nelson Peltz is taking a seat on the board at Ingersoll-Rand.

  • Checking the charts on Research in Motion and the rumor that IBM is looking to buy one of RIM's main units, with Edward Snyder, Charter Equity Research, and Abigail Doolittle, Peak Theories Research.

  • Faber Report: News Corp. Earnings     Thursday, 9 Aug 2012 | 9:37 AM ET

    CNBC's David Faber breaks down the profit-making divisions within the media giant; including its cable, film, television, satellite and publishing units.

  • Is Samsung a Good Buyer for RIM?     Wednesday, 8 Aug 2012 | 10:45 AM ET

    Peter Misek, Jefferies senior tech analyst, explains why Samsung could be a potential candidate to purchase Research in Motion.

  • Triumph: Profits Soar, Earnings Fly     Tuesday, 7 Aug 2012 | 7:15 AM ET

    Richard Ill, Triumph Group chairman, explains how the aircraft supplier has managed to gain from Boeing's loss and profit from recent takeovers.

  • Featured Speaker - Henry R. Kravis Monday, 16 Jul 2012 | 12:04 PM ET
    Henry R. Kravis, Co-Chairman and Co-CEO, KKR

    The co-founder of the trailblazing private-equity firm Kohlberg Kravis Roberts is actively involved in managing the firm famous for its leveraged buyout of RJR Nabisco 25 years ago.

  • Glaxo to Buy Human Genome Sciences     Monday, 16 Jul 2012 | 10:26 AM ET

    CNBC's David Faber reports Glaxo will buy Human Genome for $14.24 per share, and TPG acquires generic drugmaker Par Pharma.

  • CNBC's David Faber reports the latest details on GlaxoSmithKline's takeover bid for Human Genome Science.

  • BlackBerry: Rotten or Ripe?     Tuesday, 10 Jul 2012 | 11:00 AM ET

    CNBC's Jon Fortt reports the latest details from RIM's annual shareholders meeting and Colin Gillis, BGC Partners analyst, discusses whether there are investment opportunities in the stock despite its downward spiral.

  • Five Stocks Ripe for Takeovers? Tuesday, 10 Jul 2012 | 8:49 AM ET

    Here are five companies that could be bought, according to analyst Ken Hackel of CT Capital, best known for his book, “Security Valuation and Risk Analysis.”

  • Cramer Answers Mad Money Mail     Monday, 2 Jul 2012 | 6:58 PM ET

    Mad Money's Jim Cramer answers e-mails from viewers on stock and investment questions.

  • Can Regeneron Continue to Grow?     Monday, 2 Jul 2012 | 2:14 PM ET

    Dr. Leonard Schleifer, Regeneron Pharmaceuticals president & CEO, discusses competition in the pharma sector and upcoming clinical trials. "One of the things that's particularly exciting for a lot of people is our approach to lowering cholesterol," says Schleifer.

  • Bristol Buying Amylin for $7.1 Billion     Monday, 2 Jul 2012 | 2:11 PM ET

    CNBC's Seema Mody discusses the details of the deal between pharma companies Bristol-Myers and Amylin.

Most Popular Video

Friday, 18 Apr 2014 | 11:00 AM ET

Are economic growth expectations too high? CNBC's Jeff Cox explains.

Friday, 18 Apr 2014 | 12:00 PM ET

CNBC's Stephanie Landsman discusses how the luxury rental boom isn't confined to New York City and its boroughs, but that developers are seeing new opportunities in New Jersey.

Thursday, 17 Apr 2014 | 12:00 PM ET

CNBC's Josh Lipton and Allison+Partners Head of Digital Jeremy Rosenberg discuss what Microsoft needs to do to boost Xbox One sales as PS4 sales break the 7 million mark.